AI Article Synopsis
- The HIMALAYA study compared the effectiveness of the STRIDE regimen (tremelimumab plus durvalumab) and durvalumab alone against sorafenib for treating unresectable hepatocellular carcinoma (HCC), a difficult-to-treat liver cancer.
- Results showed that participants receiving STRIDE lived longer and had a lower risk of worsening quality of life compared to those taking sorafenib, while those on durvalumab alone had similar survival to the sorafenib group.
- The findings indicate that STRIDE is a more effective treatment option than sorafenib for patients with unresectable HCC, with manageable side effects associated with the immunotherapy drugs.
Article Abstract
What Is This Summary About?: This is a summary of results from a phase 3 clinical study called HIMALAYA. HIMALAYA looked at treatment with one dose of a medication called tremelimumab combined with multiple doses of a medication called durvalumab (the STRIDE regimen) or multiple doses of durvalumab alone. These treatments were compared with a medication called sorafenib in participants with unresectable hepatocellular carcinoma (HCC). HCC is a type of liver cancer that is difficult to treat because it is often diagnosed when it is unresectable, meaning it can no longer be removed with surgery. Sorafenib has been the main treatment for unresectable HCC since 2007. However, people who take sorafenib may experience side effects that can reduce their quality of life, so alternative medicines are being trialed. Tremelimumab and durvalumab are types of drugs called immunotherapies, and they both work in different ways to help the body's immune system fight cancer.
What Were The Results Of The Study?: Participants who took STRIDE lived longer than participants who took sorafenib, whilst participants who took durvalumab alone lived a similar length of time as participants who took sorafenib. Participants who took STRIDE or durvalumab had a lower relative risk of experiencing worsening in their quality of life than participants who took sorafenib. The side effects that participants who received STRIDE or durvalumab experienced were expected for these types of treatments and could mostly be managed.
What Do The Results Of The Study Mean?: Overall, STRIDE is more effective than sorafenib for people with unresectable HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fon-2023-0486 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
RHCE genotyping using next generation sequencing: Allele specific reference sequences.
Transfusion
December 2024
School of Biomedical Sciences, Faculty of Health, University of Plymouth, Plymouth, UK.
Background: The Rh blood group system (ISBT004) is encoded by two homologous genes, RHD and RHCE. Polymorphism in these two genes gives rise to 56 antigens, which are highly immunogenic and clinically significant. This study extended previous work on the establishment of RHD allele specific reference sequences using next generation sequencing (NGS) with the Ion Personal Genome Machine (Ion PGM) to sequence the complete RHCE gene.
View Article and Find Full Text PDFSociety of Family Planning Clinical Recommendation: Medication management for early pregnancy loss.
Contraception
December 2024
Planned Parenthood South Atlantic, Raleigh, NC, USA and McLeod Regional Medical Center, Florence, SC, USA; University of Washington Department of Obstetrics and Gynecology, 1959 NE Pacific St, Box 356460, Seattle, WA 98005, USA; Pegasus Health Justice Center, Dallas, TX, 75207, USA; Washington University, St. Louis, MO, USA.
Early pregnancy loss (EPL), also known as miscarriage or spontaneous abortion, makes up 15-20% of all clinically recognized pregnancies. EPL is a broad term that includes intrauterine pregnancies (IUPs) with findings that suggest the pregnancy may not progress or definitely will not progress; pregnancies with a gestational sac (GS) in the lower endometrial cavity or endocervical canal in the process of expulsion; residual pregnancy tissue or persistent GS; and complete passage of the GS without residual tissue. This document addresses medication management of EPL in which the complete passage of the GS has not yet occurred, including pregnancies concerning for and diagnostic of EPL (sometimes called "missed abortion") and EPL in progress.
View Article and Find Full Text PDFScreening for diseases versus screening for health status.
J Clin Epidemiol
December 2024
Ottawa Hospital Research Institute, Ottawa, Canada; School of Epidemiology and Public Health, University of Ottawa, Ottawa, Canada; Department of Obstetrics and Gynecology, University of Ottawa, Ottawa, Canada; International and Global Health Office, University of Ottawa Faculty of Medicine, Ottawa, Canada; BORN Ontario, Children's Hospital of Eastern Ontario, Ottawa, Canada.
Disease screening aims to identify individuals at risk for specific conditions. It is expected that an early detection allows for early intervention, with improved outcomes. However, large scale screening programs may not only have implications on resources, patient outcomes may not improve but may worsen if screening for the targeted disease has not been carefully designed and executed.
View Article and Find Full Text PDFDelivering the News of an Intraoperative Death; Literature Based Guidance from the AATS Wellness Committee.
J Thorac Cardiovasc Surg
December 2024
Norton Thoracic Institute, Dignity Health, Phoenix, Arizona (nothing to disclose).
Objectives: Fortunately, operating room deaths and unexpected deaths are infrequent occurrences. However, when they occur, the surgeon is called upon to deliver this news to family and loved ones. There is a paucity of literature on this topic and little guidance preparing cardiothoracic surgeons for this important but difficult situation.
View Article and Find Full Text PDFOptimization of a digital health intervention to enhance well-being among adolescent and young adult cancer survivors: Design and methods of the EMPOWER full factorial trial.
Contemp Clin Trials
December 2024
Northwestern University Feinberg School of Medicine, Department of Medical Social Sciences, USA.
Adolescent and young adult cancer survivors (AYAs) experience clinically significant distress and have limited access to supportive care services. Interventions to enhance psychological well-being have improved positive affect and reduced depression in clinical and healthy populations and have not been routinely tested in AYA survivors. We are optimizing a web-based positive skills intervention for AYA cancer survivors called Enhancing Management of Psychological Outcomes With Emotion Regulation (EMPOWER) by: (1) determining which intervention components have the strongest effects on well-being and (2) identifying demographic and individual difference variables that mediate and moderate EMPOWER's efficacy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!